There is no immortalized SDH-deficient GIST cell line commercially available, and the currently established GIST cell lines with mutated KIT or PDGFRA cannot be used because olverembatinib is a potent inhibitor of these targets. Here, KIT is linked to gastrointestinal stromal tumor.